大麻使用与急性冠脉综合征
本研究系统检索PubMed、Google Scholar和OpenGrey,纳入85篇文献共541,518名受试者,评估大麻使用与急性冠脉综合征的关联。纳入研究包括5篇I级系统综述、14项II级研究(83,961名受试者)和14项III级研究(457,495名受试者),其中28/33篇文献提示大麻使用增加急性冠脉综合征和慢性心血管疾病风险。另有51篇IV级病例系列和V级病例报告共62例,平均年龄31±12岁,60%心电图记录到ST段抬高,35%造影显示左前降支闭塞和/或狭窄,23%死亡归因于大麻相关急性冠脉综合征。结论认为大麻使用与急性冠脉综合征风险增加相关,但证据等级有限。
要点
- 5篇I级系统综述、14项II级研究(83,961例)和14项III级研究(457,495例)中,28/33篇提示大麻使用增加急性冠脉综合征和慢性心血管疾病风险。
- 62例病例系列/报告中,平均年龄31±12岁,60%心电图有ST段抬高,35%造影显示左前降支闭塞和/或狭窄,23%死亡归因于大麻相关急性冠脉综合征。
- dissent研究包括2篇系统综述(分别认为证据有限且弱、证据不确定)和2项纵向前瞻性研究及1篇回顾性综述(认为大麻使用者心梗后死亡率更低)。
- 无I级随机盲法对照研究专门探讨大麻与急性冠脉综合征的关联。
- 大麻定义为吸食的植物源性形式,排除非植物源性、非吸食大麻作为唯一病因的文献。
适用人群与场景
- 适用人群:吸食植物源性大麻的成人(病例系列/报告平均年龄31±12岁,女性占10%)。
- 研究排除:非植物源性、非吸食大麻作为唯一病因的文献。
研究设计与关键结果
- 研究类型:系统综述,检索PubMed、Google Scholar和OpenGrey,遵循PRISMA指南,最终纳入85篇文献共541,518名受试者。
- 证据分级:采用牛津循证医学中心(OCEBM)标准,无I级随机盲法对照研究;有5篇I级系统综述、14项II级研究(83,961例)和14项III级研究(457,495例)。
- 主要结果:28/33篇I-III级文献提示大麻使用增加急性冠脉综合征和慢性心血管疾病风险。
- dissent结果:2篇系统综述分别认为证据有限且弱、证据不确定;2项纵向前瞻性研究和1篇回顾性综述认为大麻使用者心梗后死亡率更低。
- 病例系列/报告:51篇IV级和V级文献共62例,女性6例(10%),平均年龄31±12岁,最高心率88±21次/分,收缩压125±32 mmHg,舒张压80±17 mmHg;37例(60%)心电图ST段抬高,22例(35%)造影示左前降支闭塞和/或狭窄,21例(34%)合并心肌病,14例(23%)死亡归因于大麻相关急性冠脉综合征。
证据类型、等级与局限
- 证据类型:系统综述,纳入随机对照试验、观察性研究、回顾性研究、病例系列和病例报告,采用牛津循证医学中心(OCEBM)指南分级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为大麻使用与急性冠脉综合征风险增加相关,但证据以观察性研究和病例报告为主,无I级随机对照研究。
- 病例报告提示大麻相关急性冠脉综合征患者较年轻(平均31±12岁),常见ST段抬高(60%)和左前降支病变(35%),应纳入年轻急性冠脉综合征患者的病因考虑。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Cannabis smoking can result in elevation of heart rate and blood pressure immediately after use, possibly from sympathetic nervous system stimulation and parasympathetic nervous system inhibition. Vascular inflammation, platelet activation, and carboxyhemoglobin generation have also been proposed as potential side effects of cannabis smoking. As such, an association between cannabis use and acute coronary syndrome has been postulated. Objective: The objective of our study was to analyze systematically the medical literature pertaining to this putative association. Methods: PubMed, Google Scholar, and OpenGrey were queried using a unique search string. All human trials, case series, or case reports of cannabis use and acute coronary syndrome in any language were considered in the literature search. The definition of acute coronary syndrome represented a penumbra that included chest pain, angina pectoris, unstable angina, myocardial infarction, myocardial ischemia, and cardiac arrest. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines were followed. Our final search strategy included free-text words (TW): ("cannabis"[TW] OR "marijuana"[TW]) AND ("acute coronary syndrome"[TW] OR "myocardial" OR "ischemia"[TW] OR "infarction"[TW] OR "chest pain"[TW] OR "cardiac arrest"[TW] OR "angina"[TW]). To remain consistent over a span of five decades, we specifically did not include any publications with non-phytogenic, non-smoked cannabis as the sole etiology, as these are relatively recent and may possess additional pharmacologic characteristics compared to phytogenic cannabinoids. Therefore, for the purpose of this review, the term "cannabis" refers to the smoked phytogenic form. The search resulted in 325 articles. References in each selected publication were carefully hand-searched for any additional reports having relevance, and a total of 12 publications were identified in this manner. Following comparison and discussion amongst the co-authors, duplicate and non-relevant publications were removed, and a total of 85 publications involving 541,518 human subjects were selected for inclusion. Results were synthesized and reviewed by the authors for relevance. Clinical trials, observational studies, retrospective studies, case series, and case reports were graded using Oxford Centre for Evidence-based Medicine guidelines. Results: There were no Level I randomized blinded controlled studies specifically addressing the cannabis/acute coronary syndrome association. However, there were five Level I systematic reviews, 14 Level II studies with 83,961 subjects, and 14 Level III studies with 457,495 subjects. Conclusions from 28 of these 33 studies highlighted an increased risk of both acute coronary syndrome and chronic cardiovascular disease from cannabis use. The systematic reviews were wide-ranging in topic and scale, and none specifically focused on the association between cannabis use and acute coronary syndrome. The dissenting studies included two systematic reviews, one concluding there was limited and weak evidence for association of cardiovascular disease and acute coronary syndromes with cannabis use, and another citing the evidence was inconclusive. The other dissenting articles were two longitudinal prospective studies and a retrospective review concluding cannabis users had lower post-myocardial infarction mortality. There were 51 case series (Level IV) and case reports (Level V) with 62 subjects. Six cases were female (10%). Average age was 31 ± 12 years, reported maximum heart rate was 88 ± 21 bpm, systolic blood pressure was 125 ± 32 mmHg, and diastolic blood pressure was 80 ± 17 mmHg. ST-segment elevation was documented on 37 (60%) electrocardiograms, and the most common angiographic finding was left anterior descending coronary arterial occlusion and/or stenosis in 22 (35%) patients. Concomitant cardiomyopathy was described in 21 (34%) cases. There were 14 (23%) deaths attributed to acute coronary syndrome associated with cannabis use. Conclusion: There were five Level I systematic reviews, 14 Level II studies with 83,961 subjects, and 14 Level III studies with 457,495 subjects. All but five Level I-III publications highlighted an increased risk of both acute coronary syndrome and chronic cardiovascular disease associated with cannabis use.
参考来源
- Richards JR, Bing ML, Moulin AK, et al. Cannabis use and acute coronary syndrome. Clin Toxicol (Phila). 2019. PMID: 30964363. doi:10.1080/15563650.2019.1601735
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。